Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

Notable insider trades include Morrison Alex G, Director at Energy Fuels Inc (UUUU), who sold 17500 shares on Dec 18 ’24, at $5.72 each, totaling $0.10 million. On Nov 19 ’24, HIGGS DENNIS LYLE, ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and $50.00 price target for Akero Therapeutics (NASDAQ:AKRO), representing significant upside potential from the current trading price of $24.01.

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data ...

https://www.tipranks.com/news/the-fly/monopar-therapeutics-price-target-raised-to-40-from-22-at-h-c-wainwright H.C. Wainwright raised the firm’s price target on ...